Therapeutic implications of autoimmune vitiligo T cells

Autoimmunity Reviews

Volumn 5, Issue 7, 2006, Pages 486-492

  Oyarbide Valencia, Kepa ^a   van den Boorn, Jasper G ^b   Denman, Cecele J ^a   Li, Mingli ^c   Carlson, Jeremy M ^a   Hernandez, Claudia ^a   Nishimura, Michael I ^c   Das, Pranab K ^b   Luiten, Rosalie M ^b   Le Poole, I Caroline ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antigen presentation; Melanocytes; Melanosomes; T cell avidity; T cell receptors; T cells

Indexed keywords

ANTIGEN; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; GRANZYME A; PERFORIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CYTOTOXIC T LYMPHOCYTE; DEPIGMENTATION; HUMAN; LYMPHOCYTE HOMING; LYMPHOCYTIC INFILTRATION; MELANOCYTE; MELANOMA; MELANOSOME; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; VITILIGO;

ANIMALS; HUMANS; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; VITILIGO;

EID: 33747300609     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.03.012     Document Type: Review

References (40)

1. Le Poole I.C., van den Wijngaard R.M.J.G.J., Westerhof W., Dutrieux R.P., and Das P.K. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 100 6 (1993) 816-833
2. Liu J.B., Li M., Yang S., Gui J.P., Wanf H.Y., Du W.H., et al. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol 30 4 (2005) 327-331
3. Dogra S., Parsad D., Handas S., and Kanwar A.J. Late onset vitiligo: a study of 182 patients. Int J Dermatol 44 3 (2005) 193-196
4. Halder R.M., and Nootheti P.K. Ethnic skin disorders overview. J Am Acad Dermatol 48 S6 (2003) S143-S148
5. Chaturvedi S.K., Singh G., and Gupta N. Stigma experience in skin disorders: an Indian perspective. Dermatol Clin 23 4 (2005) 635-642
6. Firooz A., Bouzari N., Fallah N., Ghazisaidi B., Firoozabadi M.R., and Dowlati Y. What patients with vitiligo believe about their condition. Int J Dermatol 43 11 (2004) 811-814
7. Steel K.P., Davidson D.J., and Jackson J.J. TRP-2/DT, a new early melanoblast marker, shows that steel factor (ckit ligand) is a survival factor. Development 115 4 (1992) 1111-1119
8. Abdel Naser M.B., Wollina U., El Okby M., and El Shiemy S. Psoralens plus ultraviolet A irradiation-induced lentigines arising in vitiligo: involvement of vitiliginous and normal appearing skin. Clin Exp Dermatol 29 4 (2004) 380-382
9. Harning P., Cui J., and Bystryn J.C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 97 6 (1991) 1078-1080
10. Kemp E.H., Waterman E.A., Hawes B.E., O'Neill K., Gottumukkala R.V., Gawkrodger D.J., et al. The melanin-concentrating receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 109 7 (2002) 923-930
11. Gilhar A., Zelickson B., Ulman Y., and Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 105 5 (1995) 683-686
12. Norris D.A., Kissinger R.M., Naughton G.M., and Bystryn J.C. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 90 6 (1988) 783-789
13. Van den Wijngaard R., Wankowicz-Kalinska A., Le Poole C., Tigges B., Westerhof W., and Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 80 8 (2000) 1299-1309
14. De Boer O.J., van der Loos C.M., Hamerlinck F., Bos J.D., and Das P.K. Reappraisal of in situ immunophenotypic analysis of psoriatic skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions. Arch Dermatol Res 286 2 (1994) 87-96
15. Boissy R.E., Liu Y.Y., Medrano E.E., and Nordlund J.J. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 97 3 (1991) 395-404
16. Im S., Hann S.K., Kim H.I., Kim N.S., and Park Y.K. Biologic characteristics of cultured human melanocytes. Int J Dermatol 33 8 (1994) 556-562
17. Boissy R.E., and Manga P. On the etiology of contact/occupational vitiligo. Pigment Cell Res 17 3 (2004) 208-214
18. Kroll T.M., Bommiasamy H., Boissy R.E., Hernandez C., Nickoloff B.J., Mestril R., et al. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo. J Invest Dermatol 124 4 (2005) 798-806
19. Asea A. Stress proteins and initiation of immune response: chaperone activity of hsp72. Exerc Immunol Rev 11 (2005) 34-35
20. Somersan S., Larsson M., Fonteneau J.F., Basu S., Srivastava P., and Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 167 9 (2001) 4844-4852
21. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment with interferon. N Engl J Med 254 7 (2006) 709-718
22. Luiten R.M., Kueter E.W., Mooi W., Gullee M.P., Rankn E.M., Gerritsen W.R., et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 23 35 (2005) 8978-8991
23. Hoashi T., Watabe H., Muller J., Yamaguchi Y., Vieira V.D., and Hearin V.J. MART-1 is required for the function of the melanosomal matrix protein Pmel17/gp100 and the maturation of melanosomes. J Biol Chem 230 14 (2005) 14006-14016
24. Kawakami Y., and Rosenberg S.A. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 14 2-3 (1997) 173-192
25. Rouzaud F., Kadekaro A.L., Abdel-Malek Z.A., and Hearing V.J. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 571 1-2 (2005) 133-152
26. Taieb J., Chaput N., and Zitvogel L. Dendritic cell-derived exosomes as cell-free peptide-based vaccines. Crit Rev Immunol 25 3 (2005) 215-223
27. Orlow S.J., Boissy R.E., Moran D.J., and Pifko-Hirst S. Subcellular distribution of tyrosinase and tyrosinase-related protein-1: implications for melanosomal biogenesis. J Invest Dermatol 100 1 (1993) 55-64
28. van den Wijngaard R.M.J.G.J., Aten J., Scheepmaker A., Le Poole I.C., Tigges A.J., Westerhof W., et al. Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 143 3 (2000) 573-581
29. Kruger-Krasagakes S., Krasagakis S., Garbe C., and Diamantstein T. Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res 139 (1995) 155-168
30. Le Poole I.C., van den Wijngaard R.M., Westerhof W., Verkruisen R.P., Dutrieux R.P., Dingemans K.P., et al. Phagocytosis by normal human melanocytes in vitro. Exp Cell Res 205 2 (1993) 388-395
31. Le Poole I.C., Mutis T., van den Wijngaard R.M.J.G.J., Westerhof W., Ottnhof T., de Vries R.R., et al. A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 151 12 (1993) 7284-7292
32. Overwijk W.W., and Restifo N.P. Autoimmunity and immunotherapy of cancer: targeting the 'self' to destroy the 'other'. Crit Rev Immunol 20 6 (2000) 433-450
33. Le Poole I.C., van den Wijngaard R., Westerhof W., and Das P.K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 148 4 (1996) 1219-1228
34. Wankowicz-Kalinska A., van den Wijngaard R.M., Tigges B.J., Westerhof W., Ogg G.S., Cerundolo V., et al. Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 83 5 (2003) 683-695
35. Dupin E., Real C., Clavieux-Paranaud C., Vargot P., and Le Douarin N.M. Reversal of developmental restrictions in neural crest lineages: transition from Schwann cells to glial-melanocytic precursors in vitro. Proc Natl Acad Sci U S A 100 9 (2003) 5229-5233
36. Le Poole I.C., Stennett L.S., Bonish B.K., Dee L., Robinson J.K., Hernandez C., et al. Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin. Br J Dermatol 149 4 (2003) 739-748
37. Das P.K., van den Wijngaard R.M., Wankowicz-Kalinska A., and Le Poole I.C. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol 22 3 (2001) 130-136
38. Duval L., Schmidt H., Kaltoft K., Fode K., Jenssen J.J., Sorensen S.M., et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 12 4 (2006) 1229-1236
39. Palermo B., Garbelli S., Mantovani S., Scoccia E., DaPrada G.A., Bernabei P., et al. Qualitative difference between the cytotoxic T-lymphocyte responses to melanocyte antigens in melanoma and vitiligo. Eur J Immunol 35 11 (2005) 3153-3162
40. Dejaco C., Duftner C., Grubeck-Loebenstein B., and Schermer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117 3 (2006) 289-300